232 related articles for article (PubMed ID: 31177992)
1. Total copy number variation as a prognostic factor in adult astrocytoma subtypes.
Mirchia K; Sathe AA; Walker JM; Fudym Y; Galbraith K; Viapiano MS; Corona RJ; Snuderl M; Xing C; Hatanpaa KJ; Richardson TE
Acta Neuropathol Commun; 2019 Jun; 7(1):92. PubMed ID: 31177992
[TBL] [Abstract][Full Text] [Related]
2. Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas.
Richardson TE; Sathe AA; Xing C; Mirchia K; Viapiano MS; Snuderl M; Abdullah KG; Hatanpaa KJ; Walker JM
J Neuropathol Exp Neurol; 2021 Mar; 80(4):354-365. PubMed ID: 33755138
[TBL] [Abstract][Full Text] [Related]
3. Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas.
Mirchia K; Snuderl M; Galbraith K; Hatanpaa KJ; Walker JM; Richardson TE
Acta Neuropathol Commun; 2019 Jul; 7(1):121. PubMed ID: 31349875
[No Abstract] [Full Text] [Related]
4. MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas.
Wu CC; Jain R; Neto L; Patel S; Poisson LM; Serrano J; Ng V; Patel SH; Placantonakis DG; Zagzag D; Golfinos J; Chi AS; Snuderl M
Neuroradiology; 2019 Sep; 61(9):1023-1031. PubMed ID: 31134296
[TBL] [Abstract][Full Text] [Related]
5. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
[TBL] [Abstract][Full Text] [Related]
6. Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF
Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613
[TBL] [Abstract][Full Text] [Related]
7. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
[TBL] [Abstract][Full Text] [Related]
8. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
[TBL] [Abstract][Full Text] [Related]
9. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
10. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.
Wong QH; Li KK; Wang WW; Malta TM; Noushmehr H; Grabovska Y; Jones C; Chan AK; Kwan JS; Huang QJ; Wong GC; Li WC; Liu XZ; Chen H; Chan DT; Mao Y; Zhang ZY; Shi ZF; Ng HK
Mod Pathol; 2021 Jul; 34(7):1245-1260. PubMed ID: 33692446
[TBL] [Abstract][Full Text] [Related]
11. Molecular Characterization of "True" Low-Grade IDH-Wildtype Astrocytomas.
Richardson TE; Hatanpaa KJ; Walker JM
J Neuropathol Exp Neurol; 2021 Apr; 80(5):431-435. PubMed ID: 33829259
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E
Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198
[TBL] [Abstract][Full Text] [Related]
14. Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas.
Richardson TE; Sathe AA; Kanchwala M; Jia G; Habib AA; Xiao G; Snuderl M; Xing C; Hatanpaa KJ
J Neuropathol Exp Neurol; 2018 Jul; 77(7):542-548. PubMed ID: 29741737
[TBL] [Abstract][Full Text] [Related]
15. CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.
Yokoda RT; Cobb WS; Yong RL; Crary JF; Viapiano MS; Walker JM; Umphlett M; Tsankova NM; Richardson TE
J Neuropathol Exp Neurol; 2023 Sep; 82(10):845-852. PubMed ID: 37550258
[TBL] [Abstract][Full Text] [Related]
16. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
17. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
18. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
19. Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.
Yoda RA; Marxen T; Longo L; Ene C; Wirsching HG; Keene CD; Holland EC; Cimino PJ
J Neuropathol Exp Neurol; 2019 Nov; 78(11):1002-1010. PubMed ID: 31529048
[TBL] [Abstract][Full Text] [Related]
20. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
